Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 13/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19441162 | 1.00 | NOTUM (0.50) | NOTUMKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL29644776 | 0.87 | NOTUM (0.45) | NOTUM | |
| SCHEMBL18291341 | 0.84 | DEGS1 (0.46) | KDM4EALDH1A1HSD17B10DEGS1F10 | |
| SCHEMBL16398202 | 0.84 | NEK2 (0.52) | NOTUMKDM4EHSD17B10AKR1C3 | |
| SCHEMBL20038454 | 0.83 | NOTUM (0.50) | NOTUMKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL29891157 | 0.81 | ALDH1A1 (0.54) | KDM4EMEN1ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL22149667 | 0.81 | ALDH1A1 (0.54) | KDM4EMEN1ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL16880167 | 0.81 | ALDH1A1 (0.54) | KDM4EMEN1ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL17799085 | 0.80 | SMPD3 (0.47) | MAPTAKR1C3 | |
| SCHEMBL17054803 | 0.80 | SMPD3 (0.47) | MAPTAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640247-B1 | SYK INHIBITOR AND USE METHOD THEREFOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-01-12 | — | — | EP | disclosed |
| US-11091460-B2 | Syk inhibitor and use method therefor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-08-17 | — | — | US | disclosed |
| US-20200199101-A1 | SYK INHIBITOR AND USE METHOD THEREFOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-06-25 | — | — | US | disclosed |
| EP-3640247-A1 | SYK INHIBITOR AND USE METHOD THEREFOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091460-B2 | Syk inhibitor and use method therefor | SYK, BTK, LCK | NOTUM 31/4885KDM4E 2238/4885MEN1 2761/4885 |
| US-20200199101-A1 | SYK INHIBITOR AND USE METHOD THEREFOR | SYK, BTK, LCK | NOTUM 31/4885KDM4E 2238/4885MEN1 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.